Filings & corporate actions
- 29 OctresultsResults · Q2 FY27 · standalone-2.1%NSE
- 6 OctshareholdingShareholding · 30 Sept 2026-8.0%NSE
- 6 AugresultsResults · Q1 FY27 · standalone+1.0%NSE
- 8 JulshareholdingShareholding · 30 Jun 2026-7.1%NSE
- 21 MayresultsResults · Q4 FY26 · standalone+5.0%NSE
- 13 AprshareholdingShareholding · 31 Mar 20260.0%NSE
- 9 FebresultsResults · Q3 FY26 · standalone-1.4%NSE
- 5 JanshareholdingShareholding · 31 Dec 2025-2.0%NSE
Reaction to results · all yearsrose on day 0 in 9 of 76 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 29 Oct 2026 | -2.1% | -2.2% | — | 0.1× |
| Q1 FY27 | 6 Aug 2026 | +1.0% | +0.2% | +2.6% | 1.1× |
| Q4 FY26 | 21 May 2026 | +5.0% | +14.3% | +15.1% | 4.4× |
| Q3 FY26 | 9 Feb 2026 | -1.4% | -0.2% | -4.2% | 20.9× |
| Q2 FY26 | 4 Nov 2025 | +0.3% | -1.8% | -7.0% | 0.2× |
| Q1 FY26 | 7 Aug 2025 | -3.4% | -1.5% | -5.8% | 0.6× |
| Q4 FY25 | 20 May 2025 | -1.1% | -0.9% | +19.6% | 1.7× |
| Q3 FY25 | 4 Feb 2025 | -2.9% | -12.1% | -18.7% | 0.3× |
| Q2 FY25 | 11 Nov 2024 | -1.2% | -6.5% | +22.7% | 4.9× |
| Q1 FY25 | 7 Aug 2024 | -2.1% | -7.4% | -1.8% | 0.1× |
| Q4 FY24 | 22 May 2024 | -3.2% | -6.0% | +6.2% | 3.7× |
| Q3 FY24 | 12 Feb 2024 | -2.2% | -0.7% | -9.1% | 0.5× |
| Q2 FY24 | 8 Nov 2023 | -0.9% | -3.7% | -6.1% | 1.3× |
| Q1 FY24 | 9 Aug 2023 | -3.5% | +9.6% | -9.7% | 1.3× |
| Q4 FY23 | 24 May 2023 | -3.6% | -1.9% | +10.4% | 0.9× |
| Q3 FY23 | 3 Feb 2023 | +1.3% | -2.3% | -28.1% | 7.4× |
| Q2 FY23 | 11 Nov 2022 | -0.4% | -4.3% | +0.5% | 0.1× |
| Q1 FY23 | 1 Aug 2022 | -4.3% | -6.8% | +4.3% | 0.6× |
| Q4 FY22 | 23 May 2022 | -7.5% | -5.5% | -17.0% | 2.6× |
| Q3 FY22 | 13 Feb 2022 | -4.6% | +8.0% | +5.2% | 1.1× |
| Q2 FY22 | 10 Nov 2021 | -1.5% | +1.3% | -3.9% | 0.5× |
| Q1 FY22 | 30 Jul 2021 | -0.9% | -1.4% | +21.0% | 1.7× |
| Q4 FY21 | 27 May 2021 | -1.5% | -1.9% | -7.2% | 0.7× |
| Q3 FY21 | 30 Jan 2021 | -5.9% | -6.8% | -5.7% | 1.0× |
| Q2 FY21 | 5 Nov 2020 | -2.3% | -0.3% | +22.5% | 0.5× |
| Q1 FY21 | 7 Aug 2020 | -2.2% | -5.0% | -9.5% | 0.8× |
| Q4 FY20 | 16 Jun 2020 | -3.9% | -2.8% | -11.3% | 0.3× |
| Q3 FY20 | 1 Feb 2020 | -1.8% | +1.6% | +6.6% | 0.9× |
| Q2 FY20 | 2 Nov 2019 | -6.1% | -7.7% | -6.2% | 1.5× |
| Q1 FY20 | 10 Aug 2019 | -3.9% | -5.8% | +5.4% | 1.6× |
| Q4 FY19 | 21 May 2019 | -0.9% | -1.5% | -13.8% | 0.5× |
| Q3 FY19 | 27 Feb 2019 | +1.9% | +5.7% | +31.5% | 1.0× |
| Q2 FY19 | 9 Nov 2018 | +4.0% | +5.5% | +12.9% | 2.1× |
| Q1 FY19 | 8 Aug 2018 | -0.7% | -0.9% | +1.8% | 0.2× |
| Q4 FY18 | 20 Jun 2018 | +2.3% | -8.4% | -9.4% | 0.1× |
| Q3 FY18 | 16 Mar 2018 | -4.1% | -7.2% | -2.8% | 0.5× |
| Q2 FY18 | 22 Nov 2017 | -3.4% | -0.9% | +1.0% | 0.7× |
| Q1 FY18 | 21 Aug 2017 | +2.9% | +3.5% | -2.4% | 0.1× |
| Q4 FY17 | 12 Jun 2017 | +4.6% | +20.4% | +1.3% | 4.2× |
| Q3 FY17 | 11 Feb 2017 | -2.4% | -0.6% | -3.9% | 0.4× |
| Q2 FY17 | 8 Dec 2016 | -3.2% | -11.3% | -9.7% | 0.0× |
| Q1 FY17 | 20 Sept 2016 | — | — | — | — |
| Q4 FY16 | 1 Jun 2016 | — | — | — | — |
| Q3 FY16 | 13 Feb 2016 | — | — | — | — |
| Q2 FY16 | 9 Nov 2015 | — | — | — | — |
| Q1 FY16 | 14 Aug 2015 | — | — | — | — |
| Q4 FY15 | 30 May 2015 | — | — | — | — |
| Q3 FY15 | 20 Feb 2015 | — | — | — | — |
| Q1 FY15 | 21 Aug 2014 | — | — | — | — |
| Q4 FY14 | 30 May 2014 | — | — | — | — |
| Q3 FY14 | 27 Feb 2014 | — | — | — | — |
| Q4 FY13 | 6 Jun 2013 | — | — | — | — |
| Q3 FY13 | 12 Feb 2013 | — | — | — | — |
| Q2 FY13 | 12 Nov 2012 | — | — | — | — |
| Q1 FY13 | 21 Aug 2012 | — | — | — | — |
| Q4 FY12 | 18 May 2012 | — | — | — | — |
| Q3 FY12 | 21 Feb 2012 | — | — | — | — |
| Q2 FY12 | 14 Nov 2011 | — | — | — | — |
| Q1 FY12 | 24 Aug 2011 | — | — | — | — |
| Q4 FY11 | 6 Jun 2011 | — | — | — | — |
| Q3 FY11 | 16 Feb 2011 | — | — | — | — |
| Q2 FY11 | 1 Nov 2010 | — | — | — | — |
| Q1 FY11 | 21 Jul 2010 | — | — | — | — |
| Q4 FY10 | 24 May 2010 | — | — | — | — |
| Q3 FY10 | 27 Jan 2010 | — | — | — | — |
| Q2 FY10 | 26 Oct 2009 | — | — | — | — |
| Q1 FY10 | 30 Jul 2009 | — | — | — | — |
| Q4 FY09 | 29 May 2009 | — | — | — | — |
| Q3 FY09 | 31 Jan 2009 | — | — | — | — |
| Q2 FY09 | 1 Nov 2008 | — | — | — | — |
| Q1 FY09 | 25 Jul 2008 | — | — | — | — |
| Q4 FY08 | 29 Apr 2008 | — | — | — | — |
| Q3 FY08 | 22 Jan 2008 | — | — | — | — |
| Q2 FY08 | 24 Oct 2007 | — | — | — | — |
| Q1 FY08 | 27 Jul 2007 | — | — | — | — |
| Q4 FY07 | 4 Jun 2007 | — | — | — | — |
| Average | -1.6% | -1.4% | -0.1% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | -27.2% | -16.4% | -21.4% | -7.5% | -8.3% | -2.5% |
| Profit | — | — | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions KREBSBIO settled 73.7% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 74.4%. The latest session ranks higher than 69% of the 2,023 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.12% | -3.63% | -0.70% | +3.41% | +1.80% | -17.48% |
Valuation
Ownership
Quarterly results · standalone
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 7.3 | 6.8 | 7.0 | 5.8 |
| YoY chg | -36.6% | +11.6% | +27.4% | +38.9% |
| Net profit (₹ Cr) | (3.1) | (2.3) | (2.5) | (5.4) |
| YoY chg | — | — | — | — |
| Net margin | -43.0% | -34.4% | -35.6% | -93.2% |
| EPS | -1.45 | -1.09 | -1.15 | -2.50 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 72.74% · public 27.26%- Promoter
- Public and others
- Promoter
- 72.74%
- Public
- 27.26%
- Promoter change
- 0.00 pp
- Filed
- 6 Oct 2026
- FII
- 0.50%
- DII
- 0.00%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 0.00%
- Insurance
- 0.00%
- FPI
- 0.49%
- Retail ≤ ₹2L
- 10.75%
- HNI > ₹2L
- 8.87%
- NRI
- 1.35%
- Bodies corporate
- 5.02%
- Shareholders
- 8,533
0.00 pp QoQ
0.00 pp QoQ
0.00 pp QoQ
+0.23 pp QoQ
-0.27 pp QoQ
+0.05 pp QoQ
-0.05 pp QoQ
+0.1% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| Ipca Laboratories Limited | Promoter · Corporate | 49.65% | 1.07Cr |
| HEMALATHA RAVI | Promoter · Individual | 12.48% | 26.92L |
| AVINASH RAVI | Promoter · Individual | 9.93% | 21.40L |
| SUN PHARMACEUTICAL INDUSTRIES LTD | Corporate | 4.81% | 10.37L |
| GUTTIKONDA RAJASEKHAR | Individual | 1.86% | 4.02L |
| GUTTIKONDA VARA LAKSHMI | Individual | 1.70% | 3.67L |
| AJAY RAVI | Promoter · Individual | 0.52% | 1.13L |
| DR R T RAVI | Promoter · Individual | 0.11% | 23.5K |
| ADITYA RAVI | Promoter · Individual | 0.05% | 10.7K |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Price-band hits
Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- none on record
- Disclosures on record
- 11
No open-market insider trades among the recent disclosures.
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Bulk & block deals · 1 Oct 2026
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 1 Oct 2026 | Sell · bulk | VAIBHAV UPADHYAY | 1.20L | 66.69 | ₹80.2L |
| 1 Oct 2026 | Buy · bulk | VAIBHAV UPADHYAY | 742 | 66.78 | ₹49,551 |
| 26 Nov 2024 | Buy · bulk | GUTTIKONDA RAJASEKHAR | 1.44L | 115.85 | ₹1.7Cr |
| 19 Jul 2024 | Sell · bulk | NK SECURITIES RESEARCH PRIVATE LIMITED | 3.71L | 115.16 | ₹4.3Cr |
| 19 Jul 2024 | Buy · bulk | NK SECURITIES RESEARCH PRIVATE LIMITED | 3.71L | 114.96 | ₹4.3Cr |
| 19 Jul 2024 | Sell · bulk | N.G.C.S. (P) LTD. | 1.18L | 115.52 | ₹1.4Cr |
| 19 Jul 2024 | Buy · bulk | N.G.C.S. (P) LTD. | 1.18L | 115.39 | ₹1.4Cr |
| 13 Aug 2021 | Sell · bulk | BRESCON VENTURES PRIVATE LIMITED | 2.25L | 149.07 | ₹3.4Cr |
| 28 Dec 2020 | Sell · bulk | BRESCON VENTURES PRIVATE LIMITED | 1.00L | 137.75 | ₹1.4Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.
Exchange surveillance
- Long-term ASM · Stage I · since 5 Oct 2026 — Long-term Additional Surveillance Measure: after a sustained unusual move, trades carry a higher margin and, at later stages, settle trade-for-trade.
- Under 100 traders in 30 days · since 2 Nov 2026 — Fewer than 100 distinct investors traded it in the last 30 days.
- Zero EPS (4 quarters) · since 6 Dec 2024 — Zero EPS over the last four quarters.
- Loss making · since 23 Jan 2024 — The company reported a loss.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.
Every stock on this session →Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25A | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 13.0 | 12.0 | 12.9 | 12.9 | 11.5 | 6.1 | 5.5 | 4.2 | 7.3 | 6.8 | 7.0 | 5.8 | |
| Other income | 0.0 | 0.2 | 0.0 | 0.1 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 2.0 | 0.2 | 0.0 | |
| Total income | 13.0 | 12.2 | 12.9 | 12.9 | 11.7 | 6.4 | 5.5 | 4.2 | 7.3 | 8.8 | 7.1 | 5.8 | |
| Total expenses | 18.0 | 18.0 | 18.1 | 18.7 | 19.5 | 14.7 | 10.8 | 10.3 | 10.4 | 11.2 | 9.6 | 11.2 | |
| └ Finance costs | 1.2 | 1.3 | 1.3 | 1.4 | 1.6 | 1.6 | 1.7 | 1.7 | 1.8 | 1.9 | 1.9 | 1.9 | |
| └ Depreciation | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | |
| Profit before tax | (5.0) | (5.8) | (5.2) | (5.8) | (7.7) | (8.3) | (5.3) | (6.1) | (3.1) | (2.3) | (2.5) | (5.4) | |
| Tax expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net profit | (5.0) | (5.8) | (5.2) | (5.8) | (7.7) | (8.3) | (5.3) | (6.1) | (3.1) | (2.3) | (2.5) | (5.4) | |
| EPS | -2.31 | -2.72 | -2.40 | -2.67 | -3.59 | -3.83 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 | -2.50 | |
| Net margin | -38.35% | -48.84% | -40.12% | -44.81% | -67.49% | -135.54% | -97.14% | -147.40% | -42.98% | -34.36% | -35.58% | -93.23% | |
| PBT margin | -38.35% | -48.84% | -40.12% | -44.81% | -67.49% | -135.29% | -97.14% | -147.40% | -42.98% | -34.36% | -35.58% | -93.23% | |
| Tax rate | — | — | — | — | — | — | — | — | — | — | — | — |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 29 Oct 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 175.0 | 178.1 | 178.2 | 185.2 | 169.0 | 168.0 | 163.2 | 158.8 | |
| Current assets | 16.1 | 16.4 | 17.4 | 26.2 | 10.3 | 10.2 | 9.6 | 7.8 | |
| └ Cash & equivalents | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| └ Other bank balances | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Trade receivables | 0.5 | 1.0 | 1.9 | 2.6 | 0.1 | 0.1 | 0.0 | 0.0 | |
| └ Inventories | 11.9 | 11.1 | 9.8 | 7.7 | 6.0 | 5.8 | 5.7 | 4.2 | |
| Total equity | (99.5) | (108.4) | (119.2) | (130.1) | (146.2) | (157.7) | (162.8) | (170.6) | |
| └ Attributable to owners | (99.5) | (108.4) | (119.2) | (130.1) | (146.2) | (157.7) | (162.8) | (170.6) | |
| └ Share capital | 21.6 | 21.6 | 21.6 | 21.6 | 21.6 | 21.6 | 21.6 | 21.6 | |
| Borrowings | 183.2 | 187.8 | 193.4 | 204.6 | 212.2 | 219.4 | 224.8 | 227.0 | |
| └ Current | 10.0 | 9.8 | 9.9 | 43.7 | 51.0 | 55.6 | 61.3 | 72.5 | |
| └ Non-current | 173.2 | 178.0 | 183.5 | 160.9 | 161.3 | 163.8 | 163.6 | 154.5 | |
| Trade payables | 15.3 | 16.7 | 19.0 | 17.5 | 18.2 | 17.5 | 13.8 | 12.4 | |
| Current liabilities | 49.1 | 55.4 | 61.8 | 103.7 | 103.5 | 111.6 | 113.1 | 126.0 | |
| Total liabilities | 274.4 | 286.5 | 297.4 | 315.4 | 315.3 | 325.7 | 326.0 | 329.4 | |
| Net debt | 183.2 | 187.7 | 193.3 | 204.4 | 212.1 | 219.3 | 224.7 | 226.9 | |
| Current ratio | 0.33 | 0.30 | 0.28 | 0.25 | 0.10 | 0.09 | 0.09 | 0.06 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (26.5) | 3.1 | 2.3 | (6.3) | (7.9) | (1.7) | (1.9) | 3.0 | |
| └ Capex | (10.9) | (5.7) | (7.8) | (2.4) | (5.1) | (2.2) | (4.0) | (1.4) | |
| Free cash flow | (37.4) | (2.5) | (5.5) | (8.7) | (13.0) | (3.9) | (5.9) | 1.6 | |
| Investing cash flow | (10.9) | (5.7) | (7.8) | (2.4) | (5.0) | (2.2) | (3.6) | (1.4) | |
| Financing cash flow | 37.3 | 2.5 | 5.6 | 8.7 | 12.9 | 3.8 | 5.5 | (1.6) | |
| └ Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | (0.0) | (0.0) | 0.1 | 0.0 | 0.0 | (0.0) | (0.0) | (0.0) |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →KREBSBIO at a glance
- KREBSBIO closed at ₹57.08 on 20 Nov 2026, -0.12% on the day, -17.5% over one year, 25.7% below its 52-week high of ₹76.85.
- Delivery was 83.6% of traded quantity on 20 Nov 2026, the 69th percentile of its own 2,023 sessions with a reading (20-session average 73.7%, 1-year average 74.4%).
- Market capitalisation is ₹123 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-6.19).
- Q2 FY27 results (standalone, filed 29 Oct 2026): revenue ₹6 crore (+38.9% year on year), net profit ₹-5 crore; the price moved -2.1% on the first session after.
- Promoters held 72.74% at 30 Sept 2026, unchanged on the previous filing.
- Q3 FY27 results are expected between 3 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE